US EditionPublished • loading... • Updated
AstraZeneca's Enhertu shows promise in early-stage breast cancer treatment
Enhertu improved three-year disease-free survival to 92.4% and achieved a 67.3% complete response rate with fewer severe side effects, clinical trial data show.
- At the European Society for Medical Oncology Congress on Saturday, AstraZeneca and Daiichi Sankyo announced Enhertu's strong results in two pivotal late-stage studies.
- Enhertu, an antibody-drug conjugate described as `guided missiles`, targets HER2-positive breast cancer, which accounts for about 15% to 20% of all breast cancers.
- In one late-stage trial, patients with high-risk early HER2-positive breast cancer experienced a 53% risk reduction and 92.4% three-year disease-free rate versus Roche’s Kadcyla, while a second trial showed a 67.3% pathologic complete response.
- Combined sales of Enhertu by AstraZeneca and Daiichi Sankyo reached $3.75 billion last year, and the drug is approved in more than 75 countries.
- Company leaders argued the ADC approach can displace chemotherapy in multiple settings, while Susan Galbraith and Ken Keller urged focus on affordability and reimbursement.
Insights by Ground AI
13 Articles
13 Articles
Enhertu offers new hope for patients with early-stage breast cancer: it provides more effective treatment and milder side effects compared to traditional chemotherapy.
·Budapest, Hungary
Read Full Article
The results of the Phase 3 clinical trial 'DESTINY Breast11' have shown that treating patients with high-risk early HER2+ breast cancer before surgery with the antibody-pharmaceutical conjugate (ADC) trastuzumab deruxtecan improves the complete pathological response to standard chemotherapy treatment.
Coverage Details
Total News Sources13
Leaning Left2Leaning Right1Center6Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
L 22%
C 67%
11%
Factuality
To view factuality data please Upgrade to Premium
